Literature DB >> 15953428

Cataract progression after intravitreal triamcinolone injection.

Osman Cekiç1, Stanley Chang, Joseph J Tseng, Yusuf Akar, Gaetano R Barile, William M Schiff.   

Abstract

PURPOSE: To assess cataract progression after intravitreal triamcinolone injection.
DESIGN: Retrospective, interventional, case-control study.
METHODS: Forty-two phakic eyes of 37 patients were injected one, two, or three times with intravitreal triamcinolone for various indications. Noninjected phakic fellow eyes served as the control. The mean follow-up time for single injection was 12 months, for multiple injections was 14 months, and for control group was 13 months. Lens status, best-corrected visual acuity, and refractive errors were recorded at baseline and at each follow-up examination.
RESULTS: At the last follow-up, changes in posterior subcapsular cataract and refractive error from baseline were significantly different between single triamcinolone-injected eyes and the control group [0.7 +/- 0.2 (mean +/- SEM [arbitrary unit] vs 0.2 +/- 0.1, P = .02; and -0.5 +/- 0.1 diopter vs -0.2 +/- 0.1 diopter, P = .01, respectively). For multiple-injected eyes and control eyes, change from baseline in corticonuclear cataract (1.1 +/- 0.2 vs 0.2 +/- 0.1), posterior subcapsular cataract (1.1 +/- 0.2) and refractive error (-1.8 +/- 0.4 diopters) were significantly different (P < .001, P < .001, and P < .001, respectively). Visual acuity did not change after single injection (P = .83) and in control group (P = .19) but decreased after multiple injections (P = .006). Eleven study eyes and two control group eyes underwent cataract extraction during study period. Corticonuclear and posterior subcapsular cataract progression significantly correlated with follow-up time (P = .003 and P = .02, respectively) and number of injections (P = .01 and P = .04, respectively).
CONCLUSIONS: Single intravitreal triamcinolone injection induces posterior subcapsular cataract development, whereas multiple injections result in all-layer cataract progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15953428     DOI: 10.1016/j.ajo.2005.01.022

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  14 in total

1.  Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema.

Authors:  Figen Batioğlu; Emin Ozmert; Neslihan Parmak; Selcen Celik
Journal:  Int Ophthalmol       Date:  2007-04-24       Impact factor: 2.031

2.  Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation.

Authors:  Kenan Sonmez; Faruk Ozturk
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

3.  Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion.

Authors:  Alireza Ramezani; Hamed Esfandiari; Morteza Entezari; Siamak Moradian; Masoud Soheilian; Babak Dehsarvi; Mehdi Yaseri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-14       Impact factor: 3.117

4.  Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular oedema. Combined IVTA and laser treatment for PDR with CSMO.

Authors:  Berkant Kaderli; Remzi Avci; Oner Gelisken; Ahmet Ali Yucel
Journal:  Int Ophthalmol       Date:  2007-02-14       Impact factor: 2.031

5.  Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts.

Authors:  Ashish Thakur; Rajendra Kadam; Uday B Kompella
Journal:  Arch Ophthalmol       Date:  2011-03-14

6.  Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.

Authors:  Pascale Massin; Francesco Bandello; Justus G Garweg; Lutz L Hansen; Simon P Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U E K Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf
Journal:  Diabetes Care       Date:  2010-11       Impact factor: 19.112

Review 7.  Drug-induced ocular disorders.

Authors:  Junping Li; Ramesh C Tripathi; Brenda J Tripathi
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema.

Authors:  Rohit Shetty; Sivakami A Pai; Ajoy Vincent; Nitin Shetty; Kannan M Narayana; Babi Sinha; Bhujang K Shetty
Journal:  Doc Ophthalmol       Date:  2007-10-25       Impact factor: 2.379

9.  Predictors for 2-Year Functional and Morphological Outcomes of a Treat-and-Extend Regimen with Ranibizumab in Patients with Diabetic Macular Edema.

Authors:  Helena Giannakaki-Zimmermann; Alexandra Behrndt; Laura Hoffmann; Maria-Magdalena Guichard; Cengiz Türksever; Christian Prünte; Katja Hatz
Journal:  Ophthalmic Res       Date:  2021-01-26       Impact factor: 2.892

Review 10.  Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options.

Authors:  Josh O Wallsh; Ron P Gallemore
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.